Trial Profile
Drug-drug Interaction Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Subjects With Castration-Resistant Prostate Cancer
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Jan 2024
Price :
$35
*
At a glance
- Drugs Apalutamide (Primary) ; Fexofenadine; Midazolam; Omeprazole; Pioglitazone; Rosuvastatin; Vitamin K; Warfarin
- Indications Adenocarcinoma; Prostate cancer
- Focus Pharmacokinetics
- Sponsors Aragon Pharmaceuticals
- 02 Jan 2024 Planned End Date changed from 15 Oct 2023 to 31 Dec 2024.
- 02 Jan 2024 Status changed from completed to recruiting.
- 14 Feb 2023 Status changed from active, no longer recruiting to completed.